CA2701470A1 - Sustained delivery of compstatin analogs from gels - Google Patents

Sustained delivery of compstatin analogs from gels Download PDF

Info

Publication number
CA2701470A1
CA2701470A1 CA2701470A CA2701470A CA2701470A1 CA 2701470 A1 CA2701470 A1 CA 2701470A1 CA 2701470 A CA2701470 A CA 2701470A CA 2701470 A CA2701470 A CA 2701470A CA 2701470 A1 CA2701470 A1 CA 2701470A1
Authority
CA
Canada
Prior art keywords
compstatin analog
liquid composition
compstatin
composition
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2701470A
Other languages
English (en)
French (fr)
Inventor
Cedric Francois
Pascal Deschatelets
Paul Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2701470A1 publication Critical patent/CA2701470A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2701470A 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels Abandoned CA2701470A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US60/976,919 2007-10-02
US2646008P 2008-02-05 2008-02-05
US61/026,460 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (1)

Publication Number Publication Date
CA2701470A1 true CA2701470A1 (en) 2009-04-09

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701470A Abandoned CA2701470A1 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Country Status (12)

Country Link
US (1) US20110182877A1 (enExample)
EP (1) EP2207530A4 (enExample)
JP (1) JP2010540654A (enExample)
KR (2) KR20100094453A (enExample)
CN (1) CN101854916A (enExample)
AU (1) AU2008308657A1 (enExample)
BR (1) BRPI0817524A2 (enExample)
CA (1) CA2701470A1 (enExample)
MX (1) MX2010003630A (enExample)
RU (1) RU2505311C2 (enExample)
WO (1) WO2009046198A2 (enExample)
ZA (1) ZA201002365B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
EP2425814B1 (en) 2010-09-03 2013-06-19 Novagali Pharma S.A. A water-in-oil type emulsion for treating a disease of the eye
NZ607103A (en) 2010-09-03 2015-09-25 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
US10125171B2 (en) 2011-05-11 2018-11-13 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
CN110882376B (zh) 2012-11-15 2023-10-20 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
JP6432954B2 (ja) 2014-06-12 2018-12-05 ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体活性の変調
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
SI3250230T1 (sl) 2015-01-28 2022-01-31 Ra Pharmaceuticals, Inc. Modulatorji aktivnosti komplementa
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
HK1259307A1 (zh) 2015-10-07 2019-11-29 阿佩利斯制药有限公司 给药方案
AU2016370210A1 (en) * 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
KR20240135047A (ko) 2017-04-07 2024-09-10 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
AU2018386304B2 (en) * 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
ES2373649T3 (es) * 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
AU2006302212B2 (en) * 2005-10-08 2012-12-20 Apellis Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
PT1960422E (pt) * 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes
JP2009521506A (ja) * 2005-12-22 2009-06-04 アルコン リサーチ， リミテッド 補体因子ｈの危険である改変体をもつ患者における年齢による斑状変性の予防および処置のためのｃ３コンバターゼインヒビター
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US8580735B2 (en) * 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders

Also Published As

Publication number Publication date
RU2505311C2 (ru) 2014-01-27
CN101854916A (zh) 2010-10-06
JP2010540654A (ja) 2010-12-24
ZA201002365B (en) 2010-12-29
US20110182877A1 (en) 2011-07-28
RU2010113513A (ru) 2011-11-10
KR20100094453A (ko) 2010-08-26
EP2207530A2 (en) 2010-07-21
KR20150080007A (ko) 2015-07-08
WO2009046198A3 (en) 2009-07-16
WO2009046198A2 (en) 2009-04-09
AU2008308657A1 (en) 2009-04-09
EP2207530A4 (en) 2013-09-11
MX2010003630A (es) 2010-04-21
BRPI0817524A2 (pt) 2017-05-02

Similar Documents

Publication Publication Date Title
US20110182877A1 (en) Sustained delivery of compstatin analogs from gels
AU2006302212B2 (en) Compstatin and analogs thereof for eye disorders
US10407466B2 (en) Methods of selecting compstatin mimetics
AU2016253654A1 (en) Injectable combination therapy for eye disorders
HK1121380A (en) Compstatin and analogs thereof for eye disorders
HK1121380B (en) Compstatin and analogs thereof for eye disorders
MX2008004656A (es) Compstatina y analogos de la misma para tratar trastornos oculares

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130709

FZDE Discontinued

Effective date: 20151002